144 related articles for article (PubMed ID: 30693439)
21. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
[TBL] [Abstract][Full Text] [Related]
22. Targeting epigenetics as atherosclerosis treatment: an updated view.
Neele AE; Willemsen L; Chen HJ; Dzobo KE; de Winther MPJ
Curr Opin Lipidol; 2020 Dec; 31(6):324-330. PubMed ID: 33027226
[TBL] [Abstract][Full Text] [Related]
23. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
24. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
25. The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.
Shishikura D; Kataoka Y; Honda S; Takata K; Kim SW; Andrews J; Psaltis PJ; Sweeney M; Kulikowski E; Johansson J; Wong NCW; Nicholls SJ
Am J Cardiovasc Drugs; 2019 Feb; 19(1):49-57. PubMed ID: 30155718
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
[TBL] [Abstract][Full Text] [Related]
27. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
28. Novel HDL-based therapeutic agents.
Joy TR
Pharmacol Ther; 2012 Jul; 135(1):18-30. PubMed ID: 22465158
[TBL] [Abstract][Full Text] [Related]
29. Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.
Kulikowski E; Halliday C; Johansson J; Sweeney M; Lebioda K; Wong N; Haarhaus M; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
Kidney Blood Press Res; 2018; 43(2):449-457. PubMed ID: 29566379
[TBL] [Abstract][Full Text] [Related]
30. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
31. Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders.
Dhulkifle H; Diab MI; Algonaiah M; Korashy HM; Maayah ZH
ACS Pharmacol Transl Sci; 2024 Mar; 7(3):546-559. PubMed ID: 38481679
[TBL] [Abstract][Full Text] [Related]
32. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Picaud S; Wells C; Felletar I; Brotherton D; Martin S; Savitsky P; Diez-Dacal B; Philpott M; Bountra C; Lingard H; Fedorov O; Müller S; Brennan PE; Knapp S; Filippakopoulos P
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19754-9. PubMed ID: 24248379
[TBL] [Abstract][Full Text] [Related]
33. Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes.
Brandts J; Ray KK
Future Cardiol; 2020 Sep; 16(5):385-395. PubMed ID: 32378426
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Nicholls SJ; Gordon A; Johansson J; Wolski K; Ballantyne CM; Kastelein JJ; Taylor A; Borgman M; Nissen SE
J Am Coll Cardiol; 2011 Mar; 57(9):1111-9. PubMed ID: 21255957
[TBL] [Abstract][Full Text] [Related]
35. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Nicholls SJ; Gordon A; Johannson J; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Wong NC; Borgman MR; Nissen SE
Cardiovasc Drugs Ther; 2012 Apr; 26(2):181-7. PubMed ID: 22349989
[TBL] [Abstract][Full Text] [Related]
36. Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
Kühnast S; Fiocco M; van der Hoorn JW; Princen HM; Jukema JW
Eur J Pharmacol; 2015 Sep; 763(Pt A):48-63. PubMed ID: 25989133
[TBL] [Abstract][Full Text] [Related]
37. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
38. Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond.
Di Bartolo BA; Scherer DJ; Nicholls SJ
Arch Med Sci; 2016 Dec; 12(6):1302-1307. PubMed ID: 27904522
[TBL] [Abstract][Full Text] [Related]
39. Should we target HDL cholesterol level in lowering cardiovascular risk?
Toth PP
Pol Arch Med Wewn; 2009 Oct; 119(10):667-72. PubMed ID: 19847144
[TBL] [Abstract][Full Text] [Related]
40. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]